

Figure S1. Experimental protocol. AM251: selective CB₁ receptor antagonist; AM630: selective CB₂ cannabinoid antagonist; WIN55,212-2: non-selective cannabinoid receptor agonist; TG: trigeminal ganglion; Sp5C: trigeminal nucleus caudalis.

